Overview
5-Amino-1MQ is tracked as a supplement in Milligram's compound library. Nicotinamide N-methyltransferase (NNMT) inhibitor.
With a half-life of ~6 hours, 5-Amino-1MQ requires daily administration in most observed protocols. Taken orally, it has a bioavailability of approximately 95% via its primary route.
Half-life approximately 6 hours. Small-molecule oral compound. Very limited human pharmacokinetic data available. One-compartment model.
Mechanism of Action
5-Amino-1MQ's pharmacological activity involves the following key pathways:
Primary Mechanism
5-Amino-1MQ exerts its effects through its established pharmacological pathway. Its mechanism has been characterized in published research.
Enzyme Modulation
5-Amino-1MQ modulates specific enzymatic pathways relevant to its pharmacological effects.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
50 mg
Route
Oral
Frequency
Once daily
Duration
Ongoing
Dose
100 mg
Route
Oral
Frequency
Once daily
Duration
Ongoing
Frequently Asked Questions
What is 5-Amino-1MQ and how does it work?
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) – a cytosolic enzyme that consumes S-adenosyl-methionine (SAM) as a methyl donor and produces 1-methylnicotinamide (MNA). By blocking NNMT, the compound prevents the drain on intracellular NAD+ precursors, raising cellular NAD+ availability, which shifts metabolic activity toward fat oxidation and away from fat storage. Preclinical data show reduced body weight, white adipose mass, and adipocyte size in treated animals without affecting food intake.
Is 5-Amino-1MQ a peptide?
5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide – it is a quinoline derivative with a molecular weight of approximately 175 Da. Unlike conventional peptides, it is membrane-permeable and orally bioavailable, meaning it can be taken as a capsule without injection or reconstitution. It is often categorised alongside metabolic peptides and GLP-1 compounds in research contexts due to its overlapping fat-loss applications.
What is the recommended 5-Amino-1MQ dosage?
Human dosing is not established by clinical trials – the commonly cited range of 50–150 mg/day orally is derived from allometric scaling of animal research data and anecdotal reporting from clinics using it off-label. Most protocols suggest starting at 50 mg/day in the morning for 1–2 weeks to assess tolerance, then increasing to 100 mg/day as a standard ongoing dose. Doses above 150 mg/day are not supported by current evidence.
How long does 5-Amino-1MQ take to work?
Pharmacokinetic data in rats show a plasma half-life of approximately 6.9 hours with good oral absorption, suggesting once or twice-daily dosing reaches consistent plasma levels quickly. Metabolic effects – fat oxidation shifts and energy changes – are reported anecdotally within the first 1–2 weeks, with body composition changes typically visible over 6–12 weeks of consistent use alongside diet and exercise. No formal human timeline data is available.
Can 5-Amino-1MQ be stacked with NAD+ precursors or GLP-1 agonists?
5-Amino-1MQ is frequently combined with NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) in longevity-focused protocols, as both approaches target NAD+ availability from complementary angles – precursor supplementation versus enzyme inhibition. It is also reported in combination with GLP-1 agonists like semaglutide for compounded fat-loss protocols, though no human trial data validates this combination's safety or additive efficacy.
What are the side effects of 5-Amino-1MQ?
Preclinical studies in mice did not observe significant adverse effects at doses used for fat loss, and the compound was noted not to significantly affect food intake. In anecdotal human use, the most commonly reported effects are mild gastrointestinal discomfort and changes in appetite. Long-term safety, drug interactions, and human pharmacodynamics remain largely unstudied, and no regulatory approval or formal safety profile exists for human use.